ACADIA Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends

Pharma Giants' SG&A Expenses: A Decade of Divergence

__timestampACADIA Pharmaceuticals Inc.Taro Pharmaceutical Industries Ltd.
Wednesday, January 1, 20143274800091733000
Thursday, January 1, 20159080400087644000
Friday, January 1, 201618645600092365000
Sunday, January 1, 201725506200085656000
Monday, January 1, 201826575800088196000
Tuesday, January 1, 201932563800089971000
Wednesday, January 1, 202038866100093413000
Friday, January 1, 202139602800091355000
Saturday, January 1, 2022369090000113676000
Sunday, January 1, 2023402466000198366000
Monday, January 1, 2024218935000
Loading chart...

Unleashing the power of data

SG&A Expense Trends: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of ACADIA Pharmaceuticals Inc. and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, ACADIA's SG&A expenses surged by over 1,100%, peaking in 2023. In contrast, Taro's expenses grew by approximately 116% during the same period, with a notable spike in 2023. This divergence highlights ACADIA's aggressive expansion strategy compared to Taro's more conservative approach. Interestingly, 2024 data for ACADIA is missing, leaving room for speculation on future trends. As these companies navigate the competitive landscape, their SG&A expenses offer a window into their strategic priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025